Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Practical Guide of Current Controversies

Area of Science:

• Oncology
• Pulmonology
• Immunotherapy

Background:

• Immunotherapy has rapidly advanced as a systemic treatment for non-small cell lung cancer (NSCLC).
• Numerous Phase 3 clinical trials now investigate immunotherapy across various treatment settings: neoadjuvant, perioperative, adjuvant, and nonoperative.
• This evolving landscape necessitates a clear understanding of current data and future directions.

Purpose of the Study:

• To provide a comprehensive narrative review of immunotherapy in non-small cell lung cancer (NSCLC).
• To summarize data from key Phase 3 clinical trials in different treatment settings.
• To discuss and clarify current controversies in the clinical application of these findings.

Main Methods:

• Systematic literature search of Phase 3 clinical trials evaluating immunotherapy for NSCLC.
• Narrative synthesis of trial data focusing on efficacy and safety.
• Analysis of clinical practice controversies and expert opinions.

Main Results:

• Immunotherapy demonstrates significant efficacy in various settings for NSCLC.
• Controversies persist regarding the adjuvant role in perioperative therapy, treatment for PD-L1 negative tumors, and defining resectability.
• Optimal management strategies, including operative vs. nonoperative approaches and the role of radiation therapy, require further clarification.

Conclusions:

• Immunotherapy is a cornerstone in NSCLC treatment, with ongoing research addressing specific clinical dilemmas.
• Further research and consensus are needed to optimize immunotherapy use in diverse NSCLC patient populations and settings.
• Addressing controversies will refine treatment protocols and improve patient outcomes in non-small cell lung cancer.